Syngen Biotech Co.,Ltd. (TPEX: 8279)
Taiwan
· Delayed Price · Currency is TWD 133.00
-2.00 (-1.48%)
Oct 9, 2024, 1:30 PM CST
Syngen Biotech Co.,Ltd. Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,916 | 1,837 | 1,931 | 1,471 | 1,311 | 1,297 | Upgrade
|
| Revenue Growth (YoY) | -2.30% | -4.84% | 31.22% | 12.19% | 1.09% | 20.07% | Upgrade
|
| Cost of Revenue | 1,248 | 1,193 | 1,242 | 942.93 | 816.02 | 811.19 | Upgrade
|
| Gross Profit | 667.71 | 643.92 | 688.15 | 528.34 | 495.41 | 486.08 | Upgrade
|
| Selling, General & Admin | 332.12 | 302.88 | 262.63 | 197.02 | 194.51 | 193.35 | Upgrade
|
| Research & Development | 53.15 | 46.76 | 45.32 | 49.52 | 43.42 | 53.11 | Upgrade
|
| Operating Expenses | 386.92 | 341.06 | 325.78 | 246.86 | 236.15 | 243.19 | Upgrade
|
| Operating Income | 280.78 | 302.86 | 362.38 | 281.48 | 259.27 | 242.9 | Upgrade
|
| Interest Expense | -9.4 | -8.86 | -5.07 | -3.21 | -2.47 | -3.65 | Upgrade
|
| Interest & Investment Income | 1.87 | 1.43 | 0.61 | 0.32 | 2.24 | 0.3 | Upgrade
|
| Earnings From Equity Investments | 11.6 | 36.08 | 26.64 | 14.81 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 3.48 | -1.93 | 10.29 | -4.31 | -1.61 | -3.25 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.76 | 4.49 | 1.58 | 7.87 | 6.51 | 5.03 | Upgrade
|
| EBT Excluding Unusual Items | 291.1 | 334.07 | 396.42 | 296.95 | 263.94 | 241.32 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.13 | 0.02 | 0.21 | 0.98 | -0.35 | -0.27 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.23 | -0.28 | -0.21 | -0.63 | -0.21 | -0.8 | Upgrade
|
| Asset Writedown | - | - | - | -1.81 | - | - | Upgrade
|
| Pretax Income | 291 | 333.8 | 396.42 | 295.49 | 263.38 | 240.26 | Upgrade
|
| Income Tax Expense | 54.38 | 58.98 | 75.18 | 57.72 | 47.83 | 51.49 | Upgrade
|
| Net Income | 236.62 | 274.83 | 321.24 | 237.77 | 215.55 | 188.77 | Upgrade
|
| Net Income to Common | 236.62 | 274.83 | 321.24 | 237.77 | 215.55 | 188.77 | Upgrade
|
| Net Income Growth | -23.12% | -14.45% | 35.10% | 10.31% | 14.19% | 40.88% | Upgrade
|
| Shares Outstanding (Basic) | 27 | 27 | 27 | 27 | 27 | 24 | Upgrade
|
| Shares Outstanding (Diluted) | 27 | 27 | 27 | 27 | 27 | 24 | Upgrade
|
| Shares Change (YoY) | -0.00% | -0.01% | -0.00% | -0.01% | 12.85% | 3.99% | Upgrade
|
| EPS (Basic) | 8.73 | 10.14 | 11.85 | 8.77 | 7.95 | 7.86 | Upgrade
|
| EPS (Diluted) | 8.73 | 10.13 | 11.84 | 8.76 | 7.94 | 7.85 | Upgrade
|
| EPS Growth | -23.01% | -14.44% | 35.16% | 10.33% | 1.15% | 35.58% | Upgrade
|
| Free Cash Flow | 280.31 | 323.23 | -306.79 | 274.83 | -52.55 | 148.89 | Upgrade
|
| Free Cash Flow Per Share | 10.33 | 11.92 | -11.31 | 10.13 | -1.94 | 6.19 | Upgrade
|
| Dividend Per Share | 5.000 | 5.000 | 5.000 | 4.000 | 3.500 | 3.000 | Upgrade
|
| Dividend Growth | 0% | 0% | 25.00% | 14.29% | 16.67% | 20.00% | Upgrade
|
| Gross Margin | 34.85% | 35.05% | 35.64% | 35.91% | 37.78% | 37.47% | Upgrade
|
| Operating Margin | 14.65% | 16.49% | 18.77% | 19.13% | 19.77% | 18.72% | Upgrade
|
| Profit Margin | 12.35% | 14.96% | 16.64% | 16.16% | 16.44% | 14.55% | Upgrade
|
| Free Cash Flow Margin | 14.63% | 17.59% | -15.89% | 18.68% | -4.01% | 11.48% | Upgrade
|
| EBITDA | 372.28 | 386.21 | 432.93 | 347.82 | 321.89 | 294.15 | Upgrade
|
| EBITDA Margin | 19.43% | 21.02% | 22.42% | 23.64% | 24.54% | 22.67% | Upgrade
|
| D&A For EBITDA | 91.5 | 83.35 | 70.56 | 66.34 | 62.62 | 51.25 | Upgrade
|
| EBIT | 280.78 | 302.86 | 362.38 | 281.48 | 259.27 | 242.9 | Upgrade
|
| EBIT Margin | 14.65% | 16.48% | 18.77% | 19.13% | 19.77% | 18.72% | Upgrade
|
| Effective Tax Rate | 18.69% | 17.67% | 18.96% | 19.53% | 18.16% | 21.43% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.